Clay Siegall Biography and Net Worth

CEO of Seagen

Dr. Clay Siegall serves as the president, CEO and chairman of Seattle Genetics, the biotechnology company he founded in 1997.

The Washington-based company helps develop targeted cancer therapies to treat patients' unmet needs. Under Dr. Siegall’s leadership, Seattle Genetics has built a diverse flotilla of antibody-based cancer therapies, including ADCETRIS, which was granted accelerated FDA approval in 2011.

Since 1997, Dr. Siegall has served as one of the company’s directors, and he assumed the role of president in 2000. In 2002, he became Seattle Genetics’ CEO, and he has been the board chairman since 2004. During his tenure, the company has raised more than $675 million through public and private offerings, and it went public in 2001.

Prior to his career with Seattle Genetics, Dr. Siegall worked as a principal scientist at Bristol Myers Squibb Pharmaceutical Research Institute. From 1988 to 1991, he was a staff fellow and biotechnology fellow with the National Cancer Institute, National Institutes of Health.

Dr. Siegall has received numerous awards and accolades for his contributions to the scientific community, including being recognized as the Ernst & Young’s Entrepreneur of the Year and the Puget Sound Business Journal’s Dealmaker of the Year. He has authored over 70 publications and holds 15 patents.

Dr. Siegall currently serves on the boards of Mirna Therapeutics, Ultragenyx Pharmaceuticals and Alder Biopharmecuticals. He received his B.S. in zoology from the University of Maryland and his Ph.D. in genetics from George Washington University.

What is Clay B. Siegall's net worth?: The estimated net worth of Clay B. Siegall is at least $111.10 million as of November 21st, 2024. Dr. Siegall owns 485,693 shares of Seagen stock worth more than $111,097,417 as of December 22nd. This net worth estimate does not reflect any other investments that Dr. Siegall may own. Learn More about Clay B. Siegall's net worth.
How do I contact Clay B. Siegall?: The corporate mailing address for Dr. Siegall and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected]. Learn More on Clay B. Siegall's contact information.
Has Clay B. Siegall been buying or selling shares of Seagen?: Clay B. Siegall has not been actively trading shares of Seagen within the last three months. Learn More on Clay B. Siegall's trading history.
Who are Seagen's active insiders?: Seagen's insider roster includes Roger Dansey (Insider), David Epstein (CEO), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.

Clay B. Siegall Insider Trading History at Seagen

Clay B. Siegall Buying and Selling Activity at Seagen

Seagen Company Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Today's Range

Now: $228.74

$228.74

50 Day Range

MA: $228.74

$228.74

2 Week Range

Now: $228.74

$123.77

$228.96

Volume

86 shs

Average Volume

1,478,439 shs

Market Capitalization

$42.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.